VA Doctors See Big Health Wins With New Weight Drug

A one-year study involving 201 veterans at a VA clinic in Aurora, Colorado, revealed significant health benefits beyond weight loss for those prescribed semaglutide. Participants averaged a 10% body weight reduction, coupled with measurable improvements in blood pressure, LDL cholesterol, triglycerides, and blood sugar. The study, published in the Journal of General Internal Medicine, is the first to examine semaglutide's effectiveness within a VA weight management program under ordinary clinical conditions.

These results underscore the drug's success in a real-world setting, integrated with counseling and the VA's 'Move!' program. Obesity affects approximately 40% of veterans, driving conditions like cardiovascular disease and Type 2 diabetes. The observed weight loss and improved health markers suggest semaglutide can mitigate these risks, reducing the need for additional medications and specialist care.

Further VA research indicates GLP-1 receptor agonists may also reduce the risk of substance use disorders and suicidal ideation. A separate study found these drugs comparable in cardiovascular and kidney safety across liraglutide, semaglutide, and dulaglutide. The VA's scale allows for robust evaluation of treatments, potentially defining best practices for using these medications alongside lifestyle support for sustained health improvements.

The key question remains how quickly the VA will implement this successful model nationwide. The Aurora study demonstrates that a combined approach of medication and structured support can lead to significant clinical benefits for veterans, enhancing their quality of life and reducing the burden of chronic diseases.